Experts' Perspectives: How to Address a Lack of Diversity in Clinical Trials
March 1st 2024In the final part of our 3-part series, our panel of experts discuss what their fields and its leaders could do to make sure this lack of diversity in trials does not continue. These responses are highlighted in the following video and transcribed below.
Experts' Perspectives: How Lack of Trial Diversity Impacts Treatment Development
March 1st 2024In part 2 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our second question, which addresses how the previously established lack of diversity in clinical trials has had a direct effect on the development and application of new therapies or devices in real-world settings.
Experts' Perspective: How a Historic Lack of Diversity Manifests in Real-World Care
March 1st 2024In part 1 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our first question, which sought to encapsulate the perspectives of our group of experts on how a historic lack of diversity in clinical trials has manifested itself in today’s care of patients from diverse backgrounds.
New Insight: Role of Contract Research Organizations in Retina w/ Brad Doerschuk
February 29th 2024The latest episode of New Insight with Veeral Sheth, MD features a conversation with Brad Doerschuk, the CEO of InFocus Clinical Research, on the important role of contract research organizations in ophthalmology research.
What Does the FDA Approval of Roflumilast Mean for Patients with Seborrheic Dermatitis?
In this interview, Neal Bhatia, MD, reacts to the FDA’s approval of roflumilast foam as well as the approval’s background and implications for patients with the inflammatory skin condition.